The College of American Pathologists (CAP) and other organizations representing clinical labs have encouraged the Trump Transition Team to recommend the incoming Donald Trump administration rescind the FDA’s LDT rule. Additionally, a federal lawsuit challenging the FDA’s authority to regulate LDTs is still pending.
For the full article click here: ARUP Healthcare Advisory Services Can Help Labs Strengthen Quality Management as New FDA Regulations Loom